Intrinsiqq

Picard Medical, Inc. (PMI) Quality Score

PMI
Quality30

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation

Growth

Earnings Multiple
0/100
-0.3x

Negative earnings, no valuation support

Revenue Growth
100/100
19.7%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
0/100
1193.7%

Heavy dilution above 5%

Margin Trend
100/100
+63.9pp

Expanded 3+pp, strong improvement

Capital Structure
0/100
$273000

Positive debt with no FCF to service it

2024
$96000
$951000
2025
$7M
$527000
TTM
$38000
$311000
Return on Capital
0/100
-321.9%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Picard Medical (PMI) quality: score, margins and returns

Picard Medical (PMI) scores 30/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 5 metrics each scored 0 to 100, on -248.4% operating margins and -321.9% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Picard Medical (PMI) a high-quality business?+

Picard Medical scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -248.4% operating margin and a -321.9% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Picard Medical's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from PMI's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Picard Medical scores well and where it falls behind.

What is Picard Medical's return on invested capital (ROIC)?+

Picard Medical earns about -321.9% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to PMI's margins and growth on this scorecard to judge durability.

How profitable is Picard Medical?+

Picard Medical runs an operating margin of about -248.4% and a net margin of about -444.8%. Revenue has grown at roughly 12.5% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

SourceQuality score computed from the 10-Q filed 19 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 20 Aug 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Related stocks: Surgical & Medical Instruments & Apparatus

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.